Tip · Tracking

Extended biomarker panel

Q: Why ApoB if I already have LDL-C?

Because LDL-C does not reliably predict the ApoB value. In a nationally representative sample of 12,688 adults, the 95 percent distribution of ApoB at an LDL-C of 100 mg/dl ranged from 66 to 99 mg/dl, and this scatter was also found in metabolically healthy people. In the UK Biobank, moreover, only ApoB remained associated with myocardial infarction in the joint analysis, not non-HDL cholesterol or triglycerides.

Q: What ApoB value is good?

There is not yet a uniform target value as there is for LDL-C. The practical translation comes from the population distribution: an LDL-C of 70 mg/dl corresponds to a median ApoB of 60 mg/dl, an LDL-C of 100 mg/dl to an ApoB of 80 mg/dl. Which target applies to you depends on your overall risk, not on a number on the lab report.

Q: My hsCRP is elevated – do I need to worry?

First of all: was the value measured while free of inflammation? An infection, an injury or hard training drive it up. If the value is consistently elevated: the prognostic association is well established, but the added benefit for risk prediction is small, with a gain in the C-index of 0.0039 and one event prevented per 400 to 500 people screened over ten years, and only at intermediate risk.

Q: Is homocysteine still worth measuring at all?

Not as a cardiovascular marker. The Cochrane review of 15 randomized trials with 71,422 participants and high quality of evidence found no difference in myocardial infarction or all-cause mortality when homocysteine was lowered with B vitamins. For stroke there was a small difference. The value remains useful as a functional indication of a B12 or folate deficiency.

Q: Why fasting insulin rather than just fasting glucose?

Because insulin responds earlier: the body initially keeps blood glucose normal by producing more insulin. What matters in practice, however, is not the insulin value alone but the HOMA-IR calculated from it together with glucose. In the meta-analysis of 26,976 non-diabetics, only HOMA-IR was significantly associated with all-cause mortality, with RR 1.34; fasting insulin alone narrowly missed significance with RR 1.13 and P = 0.058.

Q: Does the panel make sense as a whole?

The individual markers do; the bundle is untested. There is no randomized trial showing that measuring these values together in people without symptoms leads to better outcomes, and for general health checks in people without symptoms, the Cochrane review with more than 233,000 participants shows a risk ratio for all-cause mortality of exactly 1.00.

Annually: hsCRP, HbA1c, ApoB, fasting insulin, homocysteine, vitamin D – the biohacker’s basic panel.

The extended panel is the part of blood diagnostics that statutory health insurance does not pay for: ApoB, hsCRP, fasting insulin, homocysteine. The tip is listed here because two of these markers have been tested directly against the standard values and perform well — and because one of them is the most instructive failure in preventive medicine.

In short

The individual markers are well validated; the bundle is untested. ApoB is the strongest: in the UK Biobank, with 389,529 people not on lipid-lowering therapy and a median follow-up of 11.1 years, only ApoB remained associated with myocardial infarction when ApoB, non-HDL cholesterol and triglycerides were analyzed together (adjusted hazard ratio per standard deviation 1.27; 95 % CI 1.15–1.40). LDL-C does not replace ApoB: at an LDL-C of 100 mg/dl, the 95 % distribution of ApoB ranged from 66 to 99 mg/dl. Homocysteine, by contrast, is finished as a cardiovascular target: across 15 randomized trials with 71,422 participants, lowering it changed neither the rate of myocardial infarction (RR 1.02) nor all-cause mortality (RR 1.01).

What is behind it

Every particle that can deposit plaque in an artery wall — LDL, VLDL, IDL, lipoprotein(a), chylomicron remnants — carries exactly one molecule of apolipoprotein B. The ApoB value therefore counts the atherogenic particles, while LDL-C measures the amount of cholesterol in these particles. Since particles carry different amounts of cholesterol, the two measures diverge.

hsCRP measures the low-grade systemic inflammation that accompanies plaque development. Fasting insulin and HOMA-IR capture how much insulin is needed to keep blood glucose normal — they reveal a disturbance before blood glucose itself becomes abnormal. That is the reason they are in the biohacking panel.

What ApoB achieves against the standard values

The decisive study compares two populations: 389,529 people from the UK Biobank in primary prevention, median age 56.0 years, median follow-up 11.1 years, and 40,430 patients with established atherosclerosis on statins. Considered individually, ApoB, non-HDL cholesterol and triglycerides were each associated with a first myocardial infarction; analyzed together, only ApoB remained significant, in both cohorts.

The second question is whether ApoB can be skipped. In a nationally representative sample of 12,688 statin-free adults, the median ApoB values for LDL-C of 55, 70, 100 and 190 mg/dl were 49, 60, 80 and 140 mg/dl — but ApoB scatters considerably around each median, at LDL-C 100 mg/dl from 66 to 99 mg/dl. The scatter was greatest with Friedewald LDL-C and was also found in metabolically healthy people.

What hsCRP and fasting insulin contribute

The association of hsCRP with cardiovascular disease is established across 160,309 people from 54 prospective studies: per standard deviation higher log CRP, a risk ratio of 1.63 for coronary heart disease and 1.37 after adjustment for conventional risk factors.

With insulin resistance, the distinction matters: in a meta-analysis of 26,976 non-diabetic adults, the pooled adjusted risk ratio for all-cause mortality was 1.13 (95 % CI 1.00–1.27; P = 0.058) for fasting insulin and 1.34 (1.11–1.62; P = 0.002) for HOMA-IR. Only the value calculated from insulin and glucose reached significance.

What is well supported

Four findings hold up. First, ApoB against the standard lipids: adjusted hazard ratio 1.27 (95 % CI 1.15–1.40; P < 0.001) per standard deviation, the only lipid marker left in the joint analysis. Second, the discordance with LDL-C: median ApoB 49, 60, 80 and 140 mg/dl for LDL-C of 55, 70, 100 and 190 mg/dl, with a 95 % distribution of 66 to 99 mg/dl at LDL-C 100. Third, hsCRP across 160,309 people from 54 studies with 27,769 events. Fourth, HbA1c below the diabetes threshold, with hazard ratios of 1.86 and 4.48 for a diabetes diagnosis and 1.23 and 1.78 for coronary heart disease.

What the studies show

Marston 2022, JAMA Cardiology

Prospective cohort analysis from the UK Biobank and two large trials. Primary prevention: 389,529 people not on lipid-lowering therapy, 224,097 (58 %) women, median follow-up 11.1 years. Secondary prevention: 40,430 patients on statins. Analyzed together, only ApoB remained significant (aHR 1.27 per standard deviation; 95 % CI 1.15–1.40; P < 0.001), and in both cohorts.

Sayed 2024, JAMA Cardiology

Cross-sectional analysis of 12,688 adults not on statin therapy from NHANES 2005–2016, median age 41.0 years. For LDL-C values of 55, 70, 100 and 190 mg/dl, the median ApoB values were 49, 60, 80 and 140 mg/dl; at LDL-C 100 mg/dl, the 95 % distribution ranged from 66 to 99 mg/dl. The scatter remained considerable even in metabolically healthy people.

Martí-Carvajal 2017, Cochrane

The most important cross-check in the entire panel. 15 randomized trials with 71,422 participants, follow-up one to 7.3 years. Compared with placebo, no difference in myocardial infarction (7.1 % versus 6.0 %; RR 1.02; high quality of evidence), none in all-cause mortality (11.7 % versus 12.3 %; RR 1.01). For stroke, a small difference (4.3 % versus 5.1 %; RR 0.90).

Emerging Risk Factors Collaboration 2012, N Engl J Med

Translates the hsCRP association into practical benefit and puts it into perspective in the process. 52 prospective studies with 246,669 participants. Adding CRP increased the C-index by 0.0039; the net reclassification improvement was 1.52 %. The authors’ model calculation: one event prevented per 400 to 500 people screened over 10 years, and only at intermediate risk.

Where the data stop

There is no study of the panel as a bundle in healthy people. All markers are validated individually in cohorts; a randomized trial testing whether measuring them together in people without symptoms leads to better outcomes does not exist. For general health checks, on the other hand, there is a very clear answer: all-cause mortality RR 1.00 (95 % CI 0.97–1.03; 11 trials; 233,298 participants; high certainty of evidence). ApoB is not undisputed either: in the Copenhagen General Population Study with 94,398 people, the adjusted hazard ratios per standard deviation were 1.16 for non-HDL cholesterol and 1.14 for ApoB — each provides information beyond the other.

How to do it

ApoB requires neither fasting nor calculation; the National Lipid Association recommends it in addition to the standard lipid profile for risk assessment and guiding therapy. The population data serve as orientation: LDL-C 70 mg/dl corresponds to a median ApoB of 60 mg/dl, LDL-C 100 mg/dl to an ApoB of 80 mg/dl. Measure hsCRP only when free of inflammation and repeat it if in doubt. Fasting insulin in the morning while fasting and together with fasting glucose, because only from both is HOMA-IR calculated, and only HOMA-IR was significantly associated with mortality. HbA1c requires no fasting and was prognostically superior to fasting glucose in the ARIC analysis. Homocysteine only with one question in mind: is there a B12 or folate deficiency.

Safety

Drawing blood is low-risk; the risks of this panel lie elsewhere. The more parameters are measured, the more likely it is that at least one falls outside the reference range without anything being wrong; the Cochrane review states that screening leads to more diagnostic and therapeutic procedures, which can do harm as well as good. hsCRP cannot be interpreted during acute inflammation — an infection, hard training or an injury drive the value up. With homocysteine, an unnecessary supplementation cascade looms: for serious adverse events, the risk ratio of B vitamin supplementation was 1.07 (95 % CI 1.00–1.14), without any benefit for myocardial infarction or mortality. Testosterone does not belong in screening. And an elevated ApoB is a reason for a conversation with a physician about overall risk, not for acting on your own.

BK-Score Supported, with caveats

Human evidence		7
Mechanism		8
Safety data		10
Hype gap		7
Track record of use		9

The markers listed are individually well validated – ApoB and HbA1c are among the best-studied risk parameters of all. What is missing is a study of this panel as a bundle in healthy people.

The score rates the state of knowledge, not the effect. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about the extended biomarker panel

Why ApoB if I already have LDL-C?